Bladder Cancer (BC) represents a clinical and social challenge due to its high incidence
and recurrence rates, as well as the limited advances in effective disease management …

Bladder cancer is a heterogeneous disease. Interpatient heterogeneity in response to a drug
limits treatment options and impairs improvement of patient survival. For example …

There is a growing need for a more accurate, real-time assessment of tumor status and the
probability of metastasis, relapse, or response to treatment. Conventional means of …

Context Neoadjuvant chemotherapy (NAC) is considered the standard treatment for muscle-
invasive bladder cancer (MIBC). However, its overall survival benefit is limited and toxicity is …

The CellSearch® system which is still considered the gold standard for the enumeration of
circulating tumor cells (CTC) utilizes antibodies against the epithelial cell adhesion molecule …

Simple Summary The correlation between immune checkpoint-programmed death-ligand 1
(PD-L1) marker and epithelial–mesenchymal transition (EMT) status may help to identify …

Introduction Liquid biopsies are used for the detection of tumor-specific elements in body
fluid. Their application in prognosis and diagnosis of muscle/non-muscle invasive bladder …

Purpose Urothelial carcinoma of the bladder (UCB) is clinically and genetically a highly
heterogeneous disease. Treatment decisions are usually based on histopathological …

Identification of tissue malignancy via biopsy is the widely accepted method in conventional
oncology. However, tissue biopsy suffers from inherent limitations such as invasiveness …

Circulating tumor cells (CTCs) are a promising biomarker for cancer liquid biopsy. To
evaluate the CTC capture bias and detection capability of the slit filter-based CTC isolation …